Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

A single dose of the psychedelic drug dimethyltryptamine (DMT), given with psychological support, rapidly reduced depressive ...

In a small clinical trial, a single dose of a psychedelic drug paired with psychotherapy produced rapid antidepressant ...

The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...

How are the first state-run psilocybin therapy programs going? Plus, psilocybin clinical trials for cancer patients dealing ...

Researchers found that a single 21.5mg dose of DMT reduced depression symptoms compared to placebo in patients with treatment ...

The New Jersey legislation reflects VETS' evolution from a grant-making nonprofit to a recognized national authority in veteran mental health policy. Since its founding in 2019, VETS has secured over ...

Denver’s Center Origin, Golden’s ETC, and Aspen’s SANCTUM all have their personal style, but their mission is the same.

Washington State lawmakers have approved a bill to legalize and regulate therapeutic use of the psychedelic psilocybin. During a hearing on Tuesday, members of the Senate Health & Long-Term Care ...

The drug – called SPL026 – was originally developed by UK firm Small Pharma, which was acquired by Canadian firm Cybin in ...